Cognition Therapeutics, Inc. (CGTX)
| Market Cap | 97.40M +251.4% |
| Revenue (ttm) | n/a |
| Net Income | -19.58M |
| EPS | -0.25 |
| Shares Out | 89.35M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 953,928 |
| Open | 1.150 |
| Previous Close | 1.140 |
| Day's Range | 1.070 - 1.150 |
| 52-Week Range | 0.222 - 3.830 |
| Beta | 1.81 |
| Analysts | Strong Buy |
| Price Target | 3.50 (+221.1%) |
| Earnings Date | May 7, 2026 |
About CGTX
Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is zervimesine, an orally delivered small molecule to protect neuronal synapses by preventing the binding of oligomers of pathogenic proteins, which is in Phase 2 clinical studies for the treatment of Alzheimer’s disease and Mild Cognitive Impairment, as well as geographic atr... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 4 analysts, the average rating for CGTX stock is "Strong Buy." The 12-month stock price target is $3.5, which is an increase of 221.10% from the latest price.
News
Cognition Therapeutics Receives Second Philanthropic Donation to Extend Ongoing Expanded Access Program for Zervimesine (CT1812) in Dementia with Lewy Bodies
PURCHASE, N.Y., May 14, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative dis...
Cognition Therapeutics reports Q1 EPS (5c), consensus (7c)
“We filed a request to meet with the Food and Drug Administration’s Division of Psychiatry to discuss our plans for a registrational study in people with dementia with Lewy body…
Cognition Therapeutics Reports Financial Results for the First Quarter 2026 and Provides Business Update
Meeting with FDA Division of Psychiatry scheduled for May 2026 expected to inform registrational plans for zervimesine in DLB psychosis PURCHASE, N.Y., May 07, 2026 (GLOBE NEWSWIRE) -- Cognition Thera...
Cognition Therapeutics Transcript: 25th Annual Needham Virtual Healthcare Conference
Preparations are underway for Phase III trials of zervimesine, focusing on DLB psychosis after strong Phase II results and regulatory feedback. The Alzheimer's START trial is fully enrolled, with results expected in Q3 2027, and both programs maintain a favorable safety profile.
Cognition Therapeutics to Present at Needham Virtual Healthcare Conference
PURCHASE, N.Y., April 07, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, announced that the Com...
Cognition Therapeutics CEO Issues Letter to Shareholders
Advancing Zervimesine (CT1812) towards late-stage trials for dementia with Lewy bodies (DLB) psychosis Fully funded $80 million Phase 2 START trial readout expected in the second half of 2027 PURCHAS...
Cognition Therapeutics Earnings Call Transcript: Q4 2025
Prioritizing zervimesine for DLB psychosis after strong phase II results, with registrational trial planning underway and positive regulatory feedback. Cash runway extends through Q2 2027, and Alzheimer's program continues with START trial results expected in 2027.
Cognition Therapeutics Reports Year End 2025 Financial Results and Provides Clinical Development Update
-Advancing zervimesine clinical development in DLB psychosis – - Meeting with FDA Division of Psychiatry expected by mid-2026 - - Management conference call at 8:30 a.m. ET today - PURCHASE, N.Y.
Cognition Therapeutics to Report Fourth Quarter and Year End 2025 Financial Results
PURCHASE, N.Y., March 23, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical-stage company developing product candidates that treat neurodegenerative disorders, (the “Com...
Cognition Therapeutics’ zervimesine shows eficacy in dementia trial
Cognition Therapeutics (CGTX) presented an analysis from the Phase 2 COG1201 SHIMMER study of zervimesine in dementia with Lewy bodies, or DLB, at the AD/PD 2026 Alzheimer’s & Parkinson’s Diseases…
Cognition Therapeutics Presents Evidence of Zervimesine's Impact on Neuropsychiatric Symptoms of Dementia with Lewy Bodies at AD/PD 2026
PURCHASE, N.Y., March 17, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative d...
Cognition Therapeutics announces plans to advance development of zervimesine
Cognition Therapeutics (CGTX) announced plans to advance development of zervimesine for the treatment of dementia with Lewy bodies psychosis, which impacts as many as 75% of patients. This follows rec...
Cognition Therapeutics Advancing Zervimesine (CT1812) for Dementia with Lewy Bodies (DLB) Psychosis
We believe regulatory strategy expedites development of potential first treatment to address DLB psychosis We believe regulatory strategy expedites development of potential first treatment to address ...
Cognition Therapeutics extends duration of EAP for zervimesine
Cognition Therapeutics (CGTX) has extended the duration of the expanded access program, EAP, for dementia with Lewy bodies. The program, which was originally expected to provide each participant with ...
Cognition Therapeutics Extends Expanded Access Program for Zervimesine (CT1812) in Dementia with Lewy Bodies
PURCHASE, N.Y., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative di...
Cognition Therapeutics completes Type C meeting with FDA for zervimesine
Cognition Therapeutics (CGTX) conducted a Type C meeting with the U.S. Food and Drug Administration on January 21, 2026. The objective of this meeting was to review plans for the…
Cognition Therapeutics Completes Type C Meeting with FDA for Zervimesine (CT1812) in Dementia with Lewy Bodies
PURCHASE, N.Y., Jan. 27, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the Company or Cognition) (NASDAQ: CGTX), a clinical stage company developing drugs that treat neurodegenerative disord...
Cognition publishes Phase 2 results on Zervimesine
Cognition Therapeutics (CGTX) announced that a manuscript entitled, “Phase 2 Study of Zervimesine in Participants with Mild-to-Moderate Dementia with Lewy Bodies” has been published in the journal, Al...
Cognition Therapeutics Publishes Phase 2 Clinical Results Showing Zervimesine's Potential to Slow the Progression of Dementia with Lewy Bodies
- Zervimesine exhibited meaningful improvement in behavioral, functional, cognitive, and movement measures compared to placebo - - Zervimesine exhibited meaningful improvement in behavioral, functiona...
Cognition Therapeutics files $300M mixed securities shelf
16:13 EST Cognition Therapeutics (CGTX) files $300M mixed securities shelf
Cognition Therapeutics Transcript: Piper Sandler 37th Annual Healthcare Conference
CT1812 demonstrated broad efficacy in DLB and Alzheimer's, especially in patients with low p-tau217, and is advancing to Phase 3 with regulatory support for composite endpoints and a six-month trial. The oral drug is well tolerated and may expand to other neurodegenerative indications.
Cognition reaches full enrollment in expanded access program for CT1812
Cognition Therapeutics (CGTX) announced that its expanded access program has reached full enrollment. Each of the individuals enrolled in the program are being treated with 100 mg of oral zervimesine…
Cognition Therapeutics presents Phase 3 plan for zervimesine in Alzheimer’s
Cognition Therapeutics (CGTX) presented plans for a registrational program for zervimesine in mild-to-moderate Alzheimer’s disease during the annual Clinical Trials on Alzheimer’s Disease conference. ...
Cognition Therapeutics Presents Phase 3 Plan for Zervimesine (CT1812) in Alzheimer's Disease at Clinical Trials on Alzheimer's Disease (CTAD) Conference
- Seeking Alignment with European Medicines Agency (EMA) at February 2026 Meeting - - Actively Evaluating Strategy Across DLB and Alzheimer's Disease -
Cognition Therapeutics price target raisd to $3 from $2 at B. Riley
B. Riley raised the firm’s price target on Cognition Therapeutics (CGTX) to $3 from $2 and keeps a Buy rating on the shares. Cognition’s Phase 2 START trial for early…